Tomorrow.Mobility Shines Light on the New Driving Forces for More Liveable and Sustainable Cities
17.11.2022 17:38:00 EET | Business Wire | Press release
(15-17 November 2022) – Tomorrow.Mobility World Congress (TMWC) is a global event, co-organised by Fira de Barcelona and EIT Urban Mobility, in the Gran Via venue of Fira de Barcelona, focused on promoting the design and adoption of new sustainable urban mobility models and jointly organised with the Smart City Expo World Congress.
Over 80 speakers such as Kelly Larson, director of the Road Safety Programme at Bloomberg Philanthropies; Karen Vancluysen, secretary general of POLIS; Marco te Brömmelstroet, professor of Future of Urban Mobility at the University of Amsterdam; Mikael Colville-Andersen, Urban Design Expert and Maria Tsavachidis, CEO of EIT Urban Mobility, participated in the more than 20 congress and talks in Tomorrow.Mobility. EIT urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, sponsored the venue of more than 20 innovative startups. At this edition, two studies produced by EIT Urban Mobility are unveiled. FULL STUDY & Press Summary in the google drive.
The 15-minute city
The 15-minute city, is a recent concept that has taken momentum in wake of the pandemic and has been picked up by many European cities. The goal is to create a city where people could reach all their basic essential social functions like living, working, commerce, healthcare, education, and entertainment at a 15-minute by walk. In Europe, more than €1bn in cycling-related infrastructure and 2,300 kilometers of new bike lanes have been spent since the pandemic began.
Three workshops were conducted with planning practitioners from the metropolitan region of Amsterdam, Ghent, Madrid, Milan, and Munich. A key output of this study is a roadmap for the implementation of ±15-minute city strategies to ensure access all citizen’s needs, and in connection with suburb areas. 15-Minute City concepts need to be adapted to local circumstances and population groups: older people walking speed is on average around 3.5 km/h while the average speed is considered 5km/h. Hence, a 15-minute walk could represent 900-1000m at an average speed, while at a reduced speed it could be 700m.
Urban Air Mobility
Given the fast pace of innovation, air mobility is expected to become a reality in Europe within 3-5 years and air space above cities could become an extension of public space on the ground. The European UAM market size is predicted to be 4.2 billion EUR by 2030, representing a 31% global share1. To set up the scenes for an inclusive urban air mobility scheme, this first study explores the different evolution perspectives of the sector. The study collected practitioners’ insights on the development and implementation of UAM from 12 European countries from the academic, public, and private sector.
Out of the sectorial experts, 89% expect that UAM applications will play a very important or important role in improving medical transport and support in medical emergency services. 63% of questionnaire respondents think that in the logistics field, UAM will play an important or a very important role in the transport of packages in industrial spaces. By contrast, only a minority of experts see a significant role in UAM applications in e-commerce and food deliveries. In terms of challenge, when moving forward with UAM, it is essential to consult citizens and it´s important for them to feel safe, where subjective safety matters as much as objective ones. Traffic noise is the second main concern raised by the study, after safety, for the development of Urban Air Mobility for European citizens.
About EIT Urban Mobility
EIT Urban Mobility, an initiative of the European Institute of Innovation and Technology (EIT), a body of the European Union, aims to accelerate solutions and the transition towards a user-centric, integrated and truly multimodal transport system. As the leading European innovation community for urban mobility, EIT Urban Mobility works to avoid fragmentation by facilitating collaboration between cities, industry, academia, research and innovation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221117005677/en/
Contact information
Press Contact Details:
Marine Moulin ‐ E:
media@eiturbanmobility.eu ‐ M: +34 654 017 463
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release
With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release
Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
